Baseline demographics
| Characteristic . | Value . |
|---|---|
| Patients, no. (% male) | 36 (97) |
| Median age, y (range) | 36.5 (21-54) |
| Baseline CD4, median cells/mm3 (range) | 161. (10-1060) |
| Baseline log10 VL, median (range) | 2.385 (1.69-5.72) |
| TIS, no. (%)* | |
| Good | 4 (11) |
| Poor | 32 (89) |
| TS, no. (%)* | |
| Good | 14 (39) |
| Poor | 22 (61) |
| Prior therapy, no. | |
| Never | 13 |
| Ever | 23 |
| Cytotoxic chemotherapy | 13† |
| Radiation | 7 |
| Other (surgery, immunotherapy, alitretinoin, thalidomide) | 11 |
| Characteristic . | Value . |
|---|---|
| Patients, no. (% male) | 36 (97) |
| Median age, y (range) | 36.5 (21-54) |
| Baseline CD4, median cells/mm3 (range) | 161. (10-1060) |
| Baseline log10 VL, median (range) | 2.385 (1.69-5.72) |
| TIS, no. (%)* | |
| Good | 4 (11) |
| Poor | 32 (89) |
| TS, no. (%)* | |
| Good | 14 (39) |
| Poor | 22 (61) |
| Prior therapy, no. | |
| Never | 13 |
| Ever | 23 |
| Cytotoxic chemotherapy | 13† |
| Radiation | 7 |
| Other (surgery, immunotherapy, alitretinoin, thalidomide) | 11 |
Kaposi sarcoma (KS) status was assessed using both the TIS system of Krown et al4 , in which poor prognosis in any category (T indicates tumor; I, immune system; or S, systemic illness) was considered overall poor prognosis (28 of the patients met the criteria of T1), and the system of Nasti et al.18
Eleven of these 13 patients had received anthracycline therapy for their KS.